Immunogenicity and Safety of GSK Biological's DTPa-HBV-IPV/Hib Vaccine or DTPa-IPV/Hib Co-administered With HBV Vaccine as Primary and Booster Vaccination in Healthy Infants Born to Hepatitis B Surface Antigen Negative Mothers

GlaxoSmithKline0 sites140 target enrollmentJanuary 2001

ConditionsHepatitis B

Overview

Phase: Phase 3
Intervention: Not specified
Conditions: Hepatitis B
Sponsor: GlaxoSmithKline
Enrollment: 140
Primary Endpoint: Seroprotective anti-HBs antibody titres above protocol specified cut-off value
Status: Completed
Last Updated: 9 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

This study will assess the immunogenicity, safety and reactogenicity of GSK Biological's DTPa-HBV-IPV/ Hib vaccine as compared to GSK's DTPa-IPV/Hib vaccine co-administered with HBV according to a three-dose immunisation course and as a booster dose in infants born to hepatitis B antigen seronegative mothers and previously primed with a birth dose of GSK's HBV vaccine.

Registry

clinicaltrials.gov

Start Date

January 2001

End Date

November 2002

Last Updated

9 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

GlaxoSmithKline

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Inclusion criteria for enrolment at birth
•Written informed consent obtained from the parents or guardians of the subject.
•A male or female infant born after a normal gestation period (between 36 and 42 weeks).
•Born to a mother seronegative for HBsAg.
•Free of obvious health problems as established by clinical examination before entering into the study.
•Inclusion criteria for administration of the combined vaccine regimen
•Between, and including, 6 and 8 weeks of age at the time of the first dose of the three-dose course of vaccination.
•Free of obvious health problems as established by medical history and clinical examination before entering into this phase of the study.
•Inclusion criteria for administration of the booster dose
•Between, and including, 15 and 18 months of age at the time of the booster vaccination.

Exclusion Criteria

•Exclusion criteria for enrolment at birth
•A family history of congenital or hereditary immunodeficiency.
•Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus infection.
•Major congenital defect(s).
•Exclusion criteria for administration of the combined vaccine regimen
•Use of any investigational or non-registered drug or vaccine other than the study vaccines within 30 days preceding the first dose of study vaccine, or planned use during the study period.
•Chronic administration Immunosuppressants or other immune-modifying drugs since birth.
•Any chronic drug therapy to be continued during the study period.
•Planned administration/ administration of a vaccine except Bacille Calmette-Guérin vaccine during the period starting from 30 days before each dose of vaccines and ending 30 days after.
•Previous vaccination against diphtheria, tetanus, pertussis or Haemophilus influenzae type b disease.

Outcomes

Primary Outcomes

Seroprotective anti-HBs antibody titres above protocol specified cut-off value

Time Frame: At the time of the second dose of combined vaccination, one month after the 3rd dose of combined vaccination and one month after the booster dose.

Secondary Outcomes

Antibody titres against all investigational vaccine antigen components(One month after first combined vaccine dose, two months after Dose 1, one month after third combined vaccine dose prior to booster vaccination and one month post-booster vaccination.)
Occurrence of solicited symptoms(During the 4-day follow-up period after each dose)
Occurrence of unsolicited symptoms(During the 30-day follow-up period after each dose of study vaccine)
Occurrence of Serious Adverse Events(From the birth dose of hepatitis B vaccine and ending with the last study visit or performance of the last study procedure or a minimum of 30 days following the third dose of the mixed vaccines and from the start of booster dose and ending a minimum of 3)